Skip to main content

CELULAS MADRE MESENQUIMALES NANO-INGENIERIZADAS PARA MEJORAR LA EFICACIA DE LOS TRASPLANTES DE CELULAS MADRE A LA SUPERFICIE OCULAR

PID2019-105525RB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre UNIVERSIDAD DE VALLADOLID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

In Vivo Confocal Microscopy in Limbal Stem Cell Deficiency After Mesenchymal Stem Cell Transplantation: A Sub-analysis from a Phase I–II Clinical Trial

  • Pérez, Inmaculada
  • Galindo, Sara
  • López-Miguel, Alberto
  • Nieto-Miguel, Teresa
  • Mata, Ana de la
  • López-Paniagua, Marina
  • Alberca, Mercedes
  • Herreras, José M.
  • Calonge, Margarita
[Introduction]: The aim of this work is to evaluate the effect of mesenchymal stem cell transplantation (MSCT) and cultivated limbal epithelial transplantation (CLET) therapies on the limbus of patients suffering from limbal stem cell deficiency (LSCD)., [Methods]: A sub-analysis of a phase I–II randomized, controlled, and double-masked clinical trial was performed to assess the changes in the anatomical structures of the limbus. In vivo confocal microscopy (IVCM) analysis was carried out in LSCD eyes before and 12 months after allogeneic MSCT or CLET. Epithelial phenotype of the central cornea, as well as the presence of transition zones and palisades of Vogt in the limbus, were assessed using Wilcoxon test., [Results]: Twenty-three LSCD (14 MSCT and nine CLET) eyes were included. The epithelial phenotype of the central cornea improved significantly (p < 0.001) from 15 (eight MSCT, seven CLET) and eight (six MSCT, two CLET) LSCD eyes showing conjunctival and mixed phenotypes, respectively, to eight (five MSCT, three CLET), five (two MSCT, three CLET), and ten (seven MSCT, three CLET) eyes showing conjunctival, mixed, and corneal phenotypes, respectively. Transition areas and palisades of Vogt were observed in at least one quadrant in nine (five MSCT, four CLET) and 16 (nine MSCT, seven CLET), and in four (two MSCT, two CLET) and six (three MSCT, three CLET) LSCD eyes before and after surgery, respectively. Changes in the transition zones and palisades were solely significant (p = 0.046) for the nasal and inferior quadrants, respectively., [Conclusions]: MSCT and CLET improved the central corneal epithelial phenotype despite only minor changes in the anatomical structures of the limbus, as detected by IVCM technology., This work was supported by Proyectos de Generación de Conocimiento Program (Grant PID2021-125142OA-I00 MCIN/AEI/10.13039/501100011033/FEDER, UE) and Retos Investigación (Grant PID2019-105525RB-100/AEI/10.13039/501100011033, MICINN/FEDER, EU) Programs, Ministry of Science and Innovation, Spain; the Advanced Therapies Program (Grant SAS/2377/2010 EC10-256), Ministry of Health, Spain; Institute of Health Carlos III, CIBER-BBN (CB06/01/003 MICINN/FEDER, EU), Spain; and the Regional Center for Regenerative Medicine and Cell Therapy, Castilla y León, Spain., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Nano-engineered mesenchymal stem cells as a platform for targeted and biologically regulated drug delivery in ocular surface inflammation

  • Gallego, Idoia
  • Marceñido, Beatriz
  • Ciriza, Jesús
  • Galindo, Sara
  • López-Paniagua, Marina
  • de la Mata, Ana
  • Puras, Gustavo
  • Calonge, Margarita
  • Pedraz, José Luis
  • Nieto-Miguel, Teresa
Transplantation of human mesenchymal stem cells (hMSCs) has demonstrated safety and efficacy in the treatment of the inflamed and damaged ocular surface in patients with limbal stem cell deficiency (LSCD). However, this strategy alone is often insufficient to fully resolve clinical signs such as corneal opacity, neovascularization, ulceration, chronic inflammation, vision loss, and pain. The aim of this work was to nano-engineer hMSCs with fluorometholone-loaded nanostructured lipid carriers (FML-NLCs) to develop a combined cell-based drug delivery strategy capable of achieving sustained drug release, enhanced in situ anti-inflammatory activity, and promoting corneal repair. FML-NLCs were characterized in terms of particle size, polydispersity index, zeta potential, morphology, encapsulation efficiency, and drug release profile. The impact of hMSC nano-engineering with FML-NLCs on cell functionality was evaluated, including viability, nanoparticle uptake, immunophenotype, differentiation potential, migration capacity, extracellular drug release profile, and anti-inflammatory activity in vitro. The results demonstrated that nano-engineered hMSCs remained viable and preserved their characteristic immunophenotype and multilineage differentiation potential. Although a modest reduction in migratory capacity was observed, FML-NLC-loaded hMSCs provided sustained extracellular drug release and exerted a potent anti-inflammatory effect on inflamed corneal epithelium. Overall, these findings demonstrate that nano-engineered hMSCs with FML-NLCs act as an effective intermediate pharmacokinetic compartment that generates a biologically regulated extracellular drug release profile and represent a promising platform for the targeted treatment of inflammatory ocular surface diseases. These findings provide the basis for future in vivo proof-of-concept studies and support the subsequent clinical translation of this strategy for the treatment of LSCD.